BFM
AQST icon

Boothbay Fund Management’s Aquestive Therapeutics AQST Stock Holding History

Boothbay Fund Management’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-137,500
Closed -$888K – 2043
2025
Q4 		$888K Buy
+137,500
New +$857K 0.01% 844

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Boothbay Fund Management's AQST Position: Q1 2024 in Review

Boothbay Fund Management sold out of Aquestive Therapeutics (AQST) in Q1 2024, closing a stake of 34,985 shares — an estimated $70.7K sold.

Boothbay Fund Management first reported a position in AQST in Q4 2019 and held it in 2 quarters. The position peaked at $483K in Q4 2019. 97 funds tracked by Wall St. Rank hold AQST as of Q1 2024.

  • Boothbay Fund Management reported no remaining Aquestive Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Boothbay Fund Management sold 34,985 Aquestive Therapeutics shares in Q1 2024, an estimated $70.7K.
  • Boothbay Fund Management first reported a position in Aquestive Therapeutics in Q4 2019 and held it in 2 quarters.
  • Boothbay Fund Management's Aquestive Therapeutics position peaked at $483K in Q4 2019.
  • 97 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q1 2024.

Based on Boothbay Fund Management's 13F filing for Q1 2024, filed 15 May 2024.